Literature DB >> 15454650

Decreased expression of interleukin 13 in human lung emphysema.

A Boutten1, M Bonay, S Laribe, G Leseche, Y Castier, V Leçon-Malas, M Fournier, G Durand, M Aubier, M Dehoux, B Crestani.   

Abstract

BACKGROUND: The overexpression of interferon (IFN)gamma or interleukin (IL)-13 in the adult murine lung induces the development of changes that mirror human lung emphysema.
METHODS: IL-13 and IFNgamma expression was determined in lung samples from five groups of PATIENTS: severe emphysema without alpha(1)-antitrypsin deficiency (SE+, n = 10); severe emphysema with alpha(1)-antitrypsin deficiency (SE-, n = 5); mild localised emphysema (ME, n = 8); non-emphysema smokers (NE-S, n = 9), and non-emphysema non-smokers (NE-NS, n = 11). Lung IL-13 and IFNgamma mRNA were analysed by RT-PCR. Lung concentrations of IL-13 protein were assessed by ELISA.
RESULTS: The expression of IFNgamma mRNA was similar in patients with or without emphysema. IL-13 mRNA was markedly decreased in the SE+ group compared with the SE- (p = 0.04), ME (p = 0.02), and non-emphysema groups (p = 0.01). IL-13 mRNA correlated with forced expiratory volume in 1 second (r = 0.5, p = 0.04) and arterial oxygen tension (r = 0.45, p = 0.03) in emphysema patients. In contrast to the non-emphysematous lung, IL-13 protein was below the detection limit of the assay in most emphysematous lung homogenates.
CONCLUSION: The lung IL-13 content is reduced in patients with severe emphysema without alpha(1)-antitrypsin deficiency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454650      PMCID: PMC1746852          DOI: 10.1136/thx.2004.025247

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  28 in total

Review 1.  Chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

2.  Amplification of inflammation in emphysema and its association with latent adenoviral infection.

Authors:  I Retamales; W M Elliott; B Meshi; H O Coxson; P D Pare; F C Sciurba; R M Rogers; S Hayashi; J C Hogg
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

Review 3.  The macrophage in chronic obstructive pulmonary disease.

Authors:  S D Shapiro
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

4.  Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells.

Authors:  G Tardif; J P Pelletier; M Dupuis; C Geng; J M Cloutier; J Martel-Pelletier
Journal:  Arthritis Rheum       Date:  1999-06

5.  Severity of elastase-induced emphysema is decreased in tumor necrosis factor-alpha and interleukin-1beta receptor-deficient mice.

Authors:  Edgar C Lucey; Joseph Keane; Ping-Ping Kuang; Gordon L Snider; Ronald H Goldstein
Journal:  Lab Invest       Date:  2002-01       Impact factor: 5.662

6.  Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema.

Authors:  Y Kasahara; R M Tuder; C D Cool; D A Lynch; S C Flores; N F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2001-03       Impact factor: 21.405

7.  Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD.

Authors:  L Segura-Valdez; A Pardo; M Gaxiola; B D Uhal; C Becerril; M Selman
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

8.  Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema.

Authors:  T Zheng; Z Zhu; Z Wang; R J Homer; B Ma; R J Riese; H A Chapman; S D Shapiro; J A Elias
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

9.  Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1).

Authors:  C G Lee; R J Homer; Z Zhu; S Lanone; X Wang; V Koteliansky; J M Shipley; P Gotwals; P Noble; Q Chen; R M Senior; J A Elias
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  Interferon gamma induction of pulmonary emphysema in the adult murine lung.

Authors:  Z Wang; T Zheng; Z Zhu; R J Homer; R J Riese; H A Chapman; S D Shapiro; J A Elias
Journal:  J Exp Med       Date:  2000-12-04       Impact factor: 14.307

View more
  7 in total

Review 1.  The cytokine network in asthma and chronic obstructive pulmonary disease.

Authors:  Peter J Barnes
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

2.  Induced sputum and bronchial mucosal expression of interleukin-13 is not increased in chronic obstructive pulmonary disease.

Authors:  S Saha; V Mistry; R Siva; D Parker; R May; P Bradding; I D Pavord; C E Brightling
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

Review 3.  Interleukin-13: prospects for new treatments.

Authors:  C E Brightling; S Saha; F Hollins
Journal:  Clin Exp Allergy       Date:  2009-10-30       Impact factor: 5.018

4.  Altered Differentiation and Inflammation Profiles Contribute to Enhanced Innate Responses in Severe COPD Epithelium to Rhinovirus Infection.

Authors:  Hong Guo-Parke; Dermot Linden; Aurelie Mousnier; Ian C Scott; Helen Killick; Lee A Borthwick; Andrew J Fisher; Sinéad Weldon; Clifford C Taggart; Joseph C Kidney
Journal:  Front Med (Lausanne)       Date:  2022-02-25

Review 5.  Eosinophilic airway inflammation in COPD.

Authors:  Shironjit Saha; Christopher E Brightling
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

6.  Association of the IL-13 polymorphisms rs1800925 and rs20541 with chronic obstructive pulmonary disease risk: An updated meta-analysis.

Authors:  Ning Liao; Hua Zhao; Min-Li Chen; Zheng-Fu Xie
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

7.  Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.

Authors:  Phuwanat Sakornsakolpat; Dmitry Prokopenko; Brian D Hobbs; Michael H Cho; Maxime Lamontagne; Nicola F Reeve; Anna L Guyatt; Victoria E Jackson; Nick Shrine; Dandi Qiao; Traci M Bartz; Deog Kyeom Kim; Mi Kyeong Lee; Jeanne C Latourelle; Xingnan Li; Jarrett D Morrow; Ma'en Obeidat; Annah B Wyss; Per Bakke; R Graham Barr; Terri H Beaty; Steven A Belinsky; Guy G Brusselle; James D Crapo; Kim de Jong; Dawn L DeMeo; Tasha E Fingerlin; Sina A Gharib; Amund Gulsvik; Ian P Hall; John E Hokanson; Woo Jin Kim; David A Lomas; Stephanie J London; Deborah A Meyers; George T O'Connor; Stephen I Rennard; David A Schwartz; Pawel Sliwinski; David Sparrow; David P Strachan; Ruth Tal-Singer; Yohannes Tesfaigzi; Jørgen Vestbo; Judith M Vonk; Jae-Joon Yim; Xiaobo Zhou; Yohan Bossé; Ani Manichaikul; Lies Lahousse; Edwin K Silverman; H Marike Boezen; Louise V Wain; Martin D Tobin
Journal:  Nat Genet       Date:  2019-02-25       Impact factor: 38.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.